At Galapagos we believe we can have a meaningful impact on the lives of millions of people who currently live with inflammatory disease and we are driven by the desire to make a difference.
Our commitment to inflammation is rooted deeply in the history o f our company. We were established over 20 years ago as a target discovery biotech company and our appr oach to drug discovery was modelled on inflammatory diseases because we believe this remains one of the greatest areas of unmet therapeutic need. Over time, our ambitious spirit and desire to improve lives thr ough bringing new and innovative medicines to patients has seen us evolve from a pure discovery company to a European Biotech.
In our approach to combatting inflammatory diseases, we are committed to listening to those living with them, to understand their daily challenges, unmet needs and desired treatment outcomes. We use these insights to inform our medicine development and focus on the he alth outcomes that truly matter to patients.
We also recognise the benefits of collaboration, where leveraging the expertise of others can help us go further and faster. We have embraced collaboration, partnering with healthcare professionals, research institutions, academia, scientists, discovery partners and patient organisations to combine expertise and accelerate our progress.
Partnering with The British Society of Gastroenterology (BSG) for the annual meeting is a fantastic opportunity to connect, engage and share important information with the wider gastroenterology community, those as committed to reducing the burden of inflammatory diseases as we are.
At this year’s BSG, Galapagos will be addressing the ‘Psychological Burden of Inflammatory Bowel Disease (IBD)’ with Dr Fiona Eldridge, Liaison Psychiatry, Psychological Medicine, Addenbrooke’s Hospital and Dr Tim Raine, Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals.
The psychological burden that IBD brings to many patients will be apparent to all who have spent time involved in the provision of care for this population. Pre vious studies have shown a higher rate of psychiatric diagnoses in the IBD patient population. But, to date, we have lacked understanding of the patients most at risk.
The session aims to uncover some of the areas of concern throug h discussion and Q&A and the presenters will share some practical tips for non-psychologists in managing patients with IBD who might need mental health support.
The session will be transmitted live on Monday 8th November at 17.15–17.55 (40 mins total).
We hope you can join us for this important discussion and look forward to seeing you there.
Job code: UK-UC-FIL-202109-00005 | Date of preparation: September 2021